Results 31 to 40 of about 3,357,233 (168)

Metabolic Regulation of Macrophages in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang, Yu Zhang, Jiali Min, Jiahui Yang, Yuchen Li, Hao Zhang, Shanshan Liu   +6 more
wiley   +1 more source

The Polymers of Life: Exploring Cellular Function Through Polymer Concepts

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Biomolecular phase separation reveals that a hidden layer of cellular organization is governed by the principles of polymer science. This review bridges polymer physics and cell biology, offering a primer on fundamental concepts, proposing a framework for interrogating cellular function, and synthesizing biophysical methods for decoding macromolecular ...
Mark Chen, Ashutosh Chilkoti
wiley   +1 more source

Posttranscriptional Regulation of PARG mRNA by HuR Facilitates DNA Repair and Resistance to PARP Inhibitors [PDF]

Cancer Research, 2017
Abstract The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity of PDAC cells to PARP inhibitors (PARPi).
Chand, Saswati N., Zarei, Mahsa, Schiewer, M. J., Sanan, Akshay R., Romeo, Carmella, Lal, Shruti, Cozzitorto, Joseph A., Nevler, Avinoam, Scolaro, Laura, Londin, Eric R., Jiang, Wei, Meisner-Kober, Nicole, Pishvaian, Michael J., Knudsen, Karen E., Yeo, Charles, Pascal, John M, Winter, Jordan M., Brody, Jonathan R.   +17 more
openaire   +2 more sources

Automodification of N‐terminal serine residues facilitates PARP2 release from DNA

The FEBS Journal, Volume 293, Issue 11, Page 3274-3287, June 2026.
PARP2 is involved in detecting DNA damage and its N‐terminal role is largely unknown. Based on biochemical and biophysical data, our findings suggest that in the presence of HPF1, N‐terminal serine 8 and 73 are enriched in auto‐ADP‐ribosylation. Our results provide insight into the mechanistic role of PARP2 N‐terminus in the PARylation‐dependent ...
Saurabh Singh Dhakar, Albert Galera‐Prat, Jin Cai, Julia Preisser, Tiila‐Riikka Kiema, Andreas Ladurner, Lari Lehtiö   +6 more
wiley   +1 more source

PARP AND PARG INHIBITION SELECTIVELY IMPAIR METABOLISM OF B-ALL CELL LINES AND INDUCE CYTOTOXICITY THROUGH DISTINCT CELL-DEATH PATHWAYS

Hematology, Transfusion and Cell Therapy
Background: Adult patients afflicted with Acute Lymphoblastic Leukemia (ALL) still represent a subset of poor prognosis, with a 5-year overall survival of around 46%.
CB Machado, KS Esteves, SCG Lima, IP Furtado, M Brandão, FMCP Pessoa, BMD Nogueira, MEA Moraes, LEB Souza, CFA Moreira-Nunes   +9 more
doaj   +1 more source

PARG inhibition induces nuclear aggregation of PARylated PARP1

bioRxiv, 2023
PARG inhibitors are currently under clinical development for the treatment of DNA repair-deficient cancers, however, their precise mechanism of action is still unclear.
Sateja Paradkar, Julia Purcell, Annie Cui, Sam Friedman, R. Sundaram, R. Jensen, R. Bindra   +6 more
semanticscholar   +1 more source

PO-496 Loss of parg drives parp inhibitor resistance in brca2-deficient mouse mammary tumours

ESMO Open, 2018
Introduction Inhibitors of poly(ADP-ribose) polymerase (PARP) have recently entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, resistance to PARP inhibitors (PARPi) is a clinical
E. Gogola, J. Jonkers, S. Rottenberg
semanticscholar   +2 more sources

Real‐World Effectiveness and Safety of Pegzilarginase Treatment in Arginase 1 Deficiency

JIMD Reports, Volume 67, Issue 3, May 2026.
ABSTRACT Pegzilarginase is the first disease‐modifying drug for arginase 1 deficiency. In clinical trials, pegzilarginase effectively normalised plasma arginine (pArg), which was associated with clinically relevant improvements in neuromotor outcomes. We report from a French early access scheme the first report on experience from pegzilarginase therapy
Anaïs Brassier, Alina Arion, Jean‐Baptiste Arnoux, Magalie Barth, Dries Dobbelaere, Magali Gorce, Michael Grövdal, Cécile Laroche, Olivia Rime, Manuel Schiff, Mattias Rudebeck   +10 more
wiley   +1 more source

Intrinsic signaling pathways modulate targeted protein degradation

Nature Communications
Targeted protein degradation is a groundbreaking modality in drug discovery; however, the regulatory mechanisms are still not fully understood. Here, we identify cellular signaling pathways that modulate the targeted degradation of the anticancer target ...
Yuki Mori, Yoshino Akizuki, Rikuto Honda, Miyu Takao, Ayaka Tsuchimoto, Sota Hashimoto, Hiroaki Iio, Masakazu Kato, Ai Kaiho-Soma, Yasushi Saeki, Jun Hamazaki, Shigeo Murata, Toshikazu Ushijima, Naoko Hattori, Fumiaki Ohtake   +14 more
doaj   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source